EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

APE1 Attenuates ALK Tyrosine Kinase Inhibitors Sensitivity in NPM1‐ALK Positive Anaplastic Large Cell Lymphoma

Zheng Liu, Xinming Jing, Dong Li iD, Lingbo Bao, Yi Liu, Ruyi Hang, Xunjie Kuang, Ziqi Jiang, Xiaoyan Dai, Xueling Tong, Gianluca Tell, Mengxia Li iD

Cancer Science · 2025

DOI: 10.1111/cas.70148 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, 2025. Verfasst von Zheng Liu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Center, Daping Hospital & Army Medical Center of PLA, Army Medical University (Third Military Medical University), Chongqing, China. Hauptthemen laut MEDLINE: Lymphoma, Large-Cell, Anaplastic, Anaplastic Lymphoma Kinase, Protein Kinase Inhibitors, DNA-(Apurinic or Apyrimidinic Site) Lyase. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Postgraduate Research & Practice Innovation Program of Chongqing Province, National Natural Science Foundation of China, the Talent Innovation and Capacity Building Program (Organized Research) of Army Medical Center of PLA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Anaplastic lymphoma kinase (ALK), a tyrosine kinase receptor of the RTK insulin superfamily, was named after its initial identification in anaplastic large cell lymphoma (ALCL). Following a reciprocal chromosomal translocation with nucleophosmin 1 (NPM1), ALK protein is abnormally expressed, promoting the malignant transformation of T cells into a more aggressive lymphoma. The inhibition of ALK activity could therefore benefit ALK+ ALCL patients. Despite the market availability and success of ALK tyrosine kinase inhibitors (TKIs), real‐world ALK+ ALCL patients exhibit significant heterogeneity in terms of disease stage at first diagnosis, tumor progression, and responses to medication. This indicates a need for more detailed differentiation of ALK+ ALCL patients in clinical practice. Here, we discovered that apurinic/apyrimidinic endonuclease‐reduction/oxidation factor 1 (APE1/REF1), an interacting partner of NPM1, could stabilize NPM1‐ALK fusion protein oligomers and enhance ALK tumor‐promoting activity and growth, decreasing cell sensitivity to ALK‐TKIs. Our results also reveal that disruption of the interaction weakens cell growth and augments the therapeutic efficacy of crizotinib and alectinib, ALK‐TKIs, against ALK+ ALCL. Thus, high expression of APE1 indicates a faster growth of ALK+ ALCL; targeting this interaction may potentially achieve improved therapeutic outcomes, providing a reference for more precise treatment of ALK+ ALCL patients in clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Large-Cell, AnaplasticAnaplastic Lymphoma KinaseProtein Kinase InhibitorsDNA-(Apurinic or Apyrimidinic Site) LyaseNuclear ProteinsHumansNucleophosminCell Line, TumorAnimalsMiceDrug Resistance, NeoplasmCell ProliferationCrizotinibXenograft Model Antitumor AssaysTyrosine Kinase InhibitorsProtein-Tyrosine Kinases

Stichwörter der Autor:innen

ALCLALK‐TKIAPE1NPM1‐ALKTKI sensitivity

Substanzen

NucleophosminNPM1 protein, humanAnaplastic Lymphoma KinaseProtein Kinase InhibitorsDNA-(Apurinic or Apyrimidinic Site) LyaseALK protein, humanAPEX1 protein, humanp80(NPM-ALK) proteinCrizotinibNuclear Proteins

Autor:innen und Institutionen

  • Cancer Center, Daping Hospital & Army Medical Center of PLA, Army Medical University (Third Military Medical University), Chongqing, China.
  • Department of Oncology, The General Hospital of Western Theater Command, Chengdu, China.
  • Department of Hypertension and Endocrinology, Center for Hypertension and Metabolic Diseases, Daping Hospital, Army Medical University (Third Military Medical University), Chongqing, China.
  • Laboratory of Molecular Biology and DNA Repair, Department of Medicine, University of Udine, Udine, Italy.

ORCID-Profile: Dong Li, Mengxia Li

Förderung

  • Postgraduate Research & Practice Innovation Program of Chongqing Province
  • National Natural Science Foundation of China
  • the Talent Innovation and Capacity Building Program (Organized Research) of Army Medical Center of PLA

Zitieren

APA

Liu, Z., Jing, X., Li, D., Bao, L., Liu, Y., Hang, R., Kuang, X., Jiang, Z., Dai, X., Tong, X., Tell, G., & Li, M. (2025). APE1 Attenuates ALK Tyrosine Kinase Inhibitors Sensitivity in NPM1‐ALK Positive Anaplastic Large Cell Lymphoma. Cancer Science. https://doi.org/10.1111/cas.70148

Vancouver

Liu Z, Jing X, Li D, Bao L, Liu Y, Hang R, et al. APE1 Attenuates ALK Tyrosine Kinase Inhibitors Sensitivity in NPM1‐ALK Positive Anaplastic Large Cell Lymphoma. Cancer Science. 2025. doi:10.1111/cas.70148

BibTeX
@article{Liu2025,
  author = {Liu, Zheng and Jing, Xinming and Li, Dong and Bao, Lingbo and Liu, Yi and Hang, Ruyi and Kuang, Xunjie and Jiang, Ziqi and Dai, Xiaoyan and Tong, Xueling and Tell, Gianluca and Li, Mengxia},
  title = {APE1 Attenuates ALK Tyrosine Kinase Inhibitors Sensitivity in NPM1‐ALK Positive Anaplastic Large Cell Lymphoma},
  journal = {Cancer Science},
  year = {2025},
  doi = {10.1111/cas.70148}
}
Kostenlos starten →